APPLICATION OF COMBINED THERAPY IN HOSPITAL PATIENTS WITH ARTERIAL HYPERTENSION AND COMORBID CHRONIC OBSTRUCTIVE PULMONARY DISEASE (19-23)

Архив в PDF формате
Дата публикации статьи в журнале: 2019/11/13
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 50, Том: 2, Страницы в выпуске: 19-23
Автор: Burtniak T.Z.
, Dnipropetrovsk medical Academy of the Ministry of health of Ukraine, PhD Student
Автор: Potabashniy V.A.
, Dnipropetrovsk medical Academy of the Ministry of health of Ukraine, Doctor of Medical Sciences
Автор: Fesenko V.I.
, Dnipropetrovsk medical Academy of the Ministry of health of Ukraine,
Анотация: The modern direction of development of internal diseases clinic and family medicine is a studying of comorbid conditions, among which in the doctor’s practice the significant part takes arterial hypertension and chronic obstructive pulmonary disease. Oscillation blood pressure worsen the prognosis, and difficulties in choosing treatment remain a serious problem in the management of patients with arterial hypertension and chronic obstructive pulmonary disease. Therefore, it is necessary to optimize the management of patients with multiple pathologies at all levels of care
DOI:
Данные для цитирования: Burtniak T.Z. Potabashniy V.A. Fesenko V.I.. APPLICATION OF COMBINED THERAPY IN HOSPITAL PATIENTS WITH ARTERIAL HYPERTENSION AND COMORBID CHRONIC OBSTRUCTIVE PULMONARY DISEASE (19-23). Восточно Европейский Научный Журнал. Медицинские науки. 2019/11/13; 50(2):19-23.

View Fullscreen
Список литературы: 1. Chazova I.E., Lazareva N.V., Oshchepkova E.V. Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and treatment efficasy (according to the national register of arterial hypertension). Therapeutic Archive. 2019; 91 (3): 4–10. DOI: 10.26442/00403660.2019.03.000110 2. Dionisios Spyratos, Lazaros Sichletidis. Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Therapeutics and Clinical Risk Management 2015:11. 481–487. 3. Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, doubleblind, placebo-controlled study. Respir Res. 2014;15:78. 4. ESH/ESC Guidelines For The Management Of Arterial Hypertension. – 2018. 5. Feshchenko Yu. I., Gavrisyuk V. K., Dzublik O. Ya., Mostovoy Y. M., Pertseva T. O., Polyanska M. O., Yachnik A. I., Yashina L. O. Adapted clinical setting: chronic obstructive pulmonary disease (Part 1)/ Yu.I. Feshchenko, V.K. Gavrisyuk, O.Ya. Dzublik, Y.M. Mostovoy, T.O. Pertseva, M.O. Polyanska, A.I. Yachnik, L.O. Yashina //Ukrainian Pulmonary Journal. 2019. - 2:5-17. DOI: 10.31215/2306-4927-2019-104-2-5- 18 6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Medical Communications Resources. –2019. 7. Karoli N.A., Dolishnya G.R., Rebrov A.P. Changes in the parameters of 24-hour blood pressure monitoring and arterial stiffness in patients with hypertension and chronic obstructive pulmonary disease treated with valsartan. Ration Pharmacother Cardiol 2014;10(1):25-30. 8. Kovalenko VM, Kornatsky VM. Problems of health and life expectancy in modern conditions / VM Kovalenko, VM Kornatsky //Textbook. –2017. –24–28. 9. Ostroumova O.D., Bondarets O.V., Guseva T.F.The value of blood pressure variability in clinical practice. Opportunities of amlodipine in reducing blood pressure variability (based on the Russian program «VARIATIONS»)/ O.D.Ostroumova, O.V.Bondarets, T.F.Guseva// Systemic Hypertension. 11 (1): 11–6. DOI: 10.26442/2075-082X_11.1.11-16 10. Sirenko YM, Mishchenko LA, Yena LM, Koval SM, Radchenko GD, Rekovets OL. Classification and standards of medical care for patients with arterial hypertension of the Association of Cardiologists of Ukraine/ YM Sirenko, LA Mishchenko, LM Yena, SM Koval, GD Radchenko, OL Rekovets// Hypertension. 2018: 4 (60): 26-47. DOI: 10.22141/2224-1485.4.60.2018.141955.


Tagged under: